Literature DB >> 2496990

Immune response to tetravalent meningococcal vaccine: opsonic and bactericidal functions of normal and properdin deficient sera.

C Söderström1, J H Braconier, H Käyhty, A G Sjöholm, B Thuresson.   

Abstract

Neisseria meningitidis serogroup W-135 appears to be a fairly common cause of infection associated with properdin deficiency or dysfunction, and anticapsular antibodies might be protective in these patients. For this reason, bactericidal and opsonophagocytic activities for serogroup W-135 were investigated before and four weeks after vaccination of two properdin-deficient adults with tetravalent meningococcal vaccine. In addition, the response of IgM, IgG and IgA class antibodies to the serogroups A, C, Y and W-135 was determined by ELISA. There was no evidence of poor antibody responses in the properdin-deficient persons. Vaccination promoted classical pathway-mediated killing in serum and opsonization of serogroup W-135 to the same extent as that seen in vaccinated controls. The increase of alternative pathway-mediated killing in the properdin-deficient sera was moderate, but vaccination clearly enhanced alternative pathway-mediated opsonophagocytosis in the sera. It was also shown that vaccination markedly reduced the requirement for properdin in alternative pathway-mediated killing of the meningococci.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496990     DOI: 10.1007/bf01965264

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination.

Authors:  P Densen; J M Weiler; J M Griffiss; L G Hoffmann
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

2.  Congenital properdin deficiency and meningococcal infection.

Authors:  H E Nielsen; C Koch
Journal:  Clin Immunol Immunopathol       Date:  1987-08

3.  Dysfunctional properdin in a Dutch family with meningococcal disease.

Authors:  A G Sjöholm; E J Kuijper; C C Tijssen; A Jansz; P Bol; L Spanjaard; H C Zanen
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

4.  Bactericidal activity for Neisseria meningitidis in properdin-deficient sera.

Authors:  C Söderström; J H Braconier; D Danielsson; A G Sjöholm
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

Review 5.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Properdin deficiency in a family with fulminant meningococcal infections.

Authors:  A G Sjöholm; J H Braconier; C Söderström
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

7.  The fate of gonococci in polymorphonuclear leucocytes.

Authors:  P J Watt
Journal:  J Med Microbiol       Date:  1970-08       Impact factor: 2.472

8.  Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response.

Authors:  E Herva; M Leinonen; H Käyhty; P H Mäkelä; S L Vetoniemi-Korhonen
Journal:  J Infect       Date:  1983-01       Impact factor: 6.072

9.  Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody.

Authors:  J G Patrick Sissons; R D Schreiber; L H Perrin; N R Cooper; H J Müller-Eberhard; M B Oldstone
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  14 in total

1.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Authors:  Monica Konar; Dan M Granoff
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

Review 2.  Complement deficiencies and meningococcal disease.

Authors:  P Densen
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 4.  Vaccination against meningococcus in complement-deficient individuals.

Authors:  B P Morgan; A Orren
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

5.  Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).

Authors:  P J Späth; A G Sjöholm; G N Fredrikson; G Misiano; R Scherz; U B Schaad; B Uhring-Lambert; G Hauptmann; J Westberg; M Uhlén; C Wadelius; L Truedsson
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  Prevalence of hereditary properdin, C7 and C8 deficiencies in patients with meningococcal infections.

Authors:  M Schlesinger; Z Nave; Y Levy; P E Slater; Z Fishelson
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

7.  Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry.

Authors:  J S Plested; B L Ferry; P A Coull; K Makepeace; A K Lehmann; F G MacKinnon; H G Griffiths; M A Herbert; J C Richards; E R Moxon
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 8.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  C A Fijen; E J Kuijper; M Drogari-Apiranthitou; Y Van Leeuwen; M R Daha; J Dankert
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 10.  Complement deficiency states and meningococcal disease.

Authors:  J Figueroa; J Andreoni; P Densen
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.